Sana Biotechnology (SANA) Financials

$2.00 +0.01 (+0.50%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.06 +0.06 (+3.00%)

As of 04:20 AM Eastern

Annual Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-267	-283	-269
Consolidated Net Income / (Loss)	-267	-283	-269
Net Income / (Loss) Continuing Operations	-267	-283	-269
Total Pre-Tax Income	-267	-283	-269
Total Operating Income	-273	-293	-273
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	273	293	273
Selling, General & Admin Expense	64	73	72
Research & Development Expense	209	220	201
Total Other Income / (Expense), net	5.96	9.89	3.09
Interest & Investment Income	10	9.94	3.76
Other Income / (Expense), net	-4.51	-0.05	-0.67
Basic Earnings per Share	($1.16)	($1.46)	($1.43)
Weighted Average Basic Shares Outstanding	230.89M	194.54M	188.34M
Diluted Earnings per Share	($1.16)	($1.46)	($1.43)
Weighted Average Diluted Shares Outstanding	230.89M	194.54M	188.34M
Weighted Average Basic & Diluted Shares Outstanding	225.02M	220.45M	191.36M

This table shows Sana Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-49	-60	-50	-107	-88	0.98	-114	-82	-80	-85
Consolidated Net Income / (Loss)	-49	-60	-50	-107	-88	0.98	-114	-82	-80	-85
Net Income / (Loss) Continuing Operations	-49	-60	-50	-107	-88	0.98	-114	-82	-80	-85
Total Pre-Tax Income	-49	-60	-50	-107	-88	0.98	-114	-82	-80	-85
Total Operating Income	-51	-62	-49	-111	-91	-2.18	-116	-84	-82	-86
Total Operating Expenses	51	62	49	111	91	2.18	116	84	82	86
Selling, General & Admin Expense	17	14	16	16	21	19	17	17	23	16
Research & Development Expense	34	48	33	94	70	-17	100	67	58	71
Total Other Income / (Expense), net	1.80	1.84	-0.92	3.25	2.46	3.17	2.29	1.98	1.35	1.07
Interest & Investment Income	1.66	2.58	3.20	3.03	2.73	2.86	2.37	1.98	1.61	1.17
Other Income / (Expense), net	0.14	-0.74	-4.12	0.22	-	0.30	-0.08	-	-0.27	-0.11
Basic Earnings per Share	($0.21)	($0.25)	($0.21)	($0.49)	($0.44)	$0.00	($0.59)	($0.43)	($0.42)	($0.45)
Weighted Average Basic Shares Outstanding	230.89M	235.41M	234.44M	217.29M	194.54M	196.98M	192.54M	191.23M	188.34M	189.30M
Diluted Earnings per Share	($0.21)	($0.25)	($0.21)	($0.49)	($0.44)	$0.00	($0.59)	($0.43)	($0.42)	($0.45)
Weighted Average Diluted Shares Outstanding	230.89M	235.41M	234.44M	217.29M	194.54M	200.47M	192.54M	191.23M	188.34M	189.30M
Weighted Average Basic & Diluted Shares Outstanding	225.02M	223.27M	222.47M	221.50M	220.45M	197.13M	196.94M	191.50M	191.36M	190.73M

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-5.95	-50	-75
Net Cash From Operating Activities	-223	-254	-290
Net Cash From Continuing Operating Activities	-223	-254	-290
Net Income / (Loss) Continuing Operations	-267	-283	-269
Consolidated Net Income / (Loss)	-267	-283	-269
Depreciation Expense	17	25	16
Non-Cash Adjustments To Reconcile Net Income	36	35	41
Changes in Operating Assets and Liabilities, net	-10	-30	-77
Net Cash From Investing Activities	17	172	211
Net Cash From Continuing Investing Activities	17	172	211
Purchase of Property, Plant & Equipment	-33	-20	-21
Purchase of Investments	-226	-158	-79
Sale and/or Maturity of Investments	277	350	310
Other Investing Activities, net	0.00	0.00	0.00
Net Cash From Financing Activities	200	32	4.91
Net Cash From Continuing Financing Activities	200	32	4.91
Issuance of Common Equity	192	32	4.91
Other Financing Activities, net	7.74	0.00	0.00

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	0.57	-7.96	-42	44	-35	-12	13	-16	13	-31
Net Cash From Operating Activities	-47	-52	-59	-66	-52	-64	-59	-79	-76	-65
Net Cash From Continuing Operating Activities	-47	-52	-59	-66	-52	-64	-59	-79	-76	-65
Net Income / (Loss) Continuing Operations	-49	-60	-50	-107	-88	0.98	-114	-82	-80	-85
Consolidated Net Income / (Loss)	-49	-60	-50	-107	-88	0.98	-114	-82	-80	-85
Depreciation Expense	5.69	4.06	3.90	3.75	11	4.50	4.45	4.35	4.20	4.02
Non-Cash Adjustments To Reconcile Net Income	5.39	9.89	13	7.55	7.82	8.41	10	9.19	11	10
Changes in Operating Assets and Liabilities, net	-9.18	-5.84	-26	31	17	-77	41	-11	-11	6.01
Net Cash From Investing Activities	47	42	5.82	-77	15	51	43	63	88	32
Net Cash From Continuing Investing Activities	47	42	5.82	-77	15	51	43	63	88	32
Purchase of Property, Plant & Equipment	-0.44	-4.09	-13	-16	-14	-2.23	-1.58	-2.18	-4.60	-4.35
Purchase of Investments	-13	-36	-63	-114	-26	-60	-51	-20	-15	-18
Sale and/or Maturity of Investments	61	82	81	53	55	114	95	85	108	54
Net Cash From Financing Activities	0.64	2.08	11	186	1.72	0.19	30	0.24	1.06	1.62
Net Cash From Continuing Financing Activities	0.64	2.08	11	186	1.72	0.19	30	0.24	1.06	1.62
Issuance of Common Equity	0.70	1.91	3.00	186	1.72	0.19	30	0.24	1.06	1.62
Other Financing Activities, net	-0.06	0.17	-	-	-	-	-	-	-	-

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	501	565	823
Total Current Assets	161	214	444
Cash & Equivalents	128	134	177
Restricted Cash	3.83	3.83	6.10
Short-Term Investments	25	72	247
Prepaid Expenses	4.48	4.49	14
Plant, Property, & Equipment, net	77	71	67
Total Noncurrent Assets	263	281	311
Long-Term Investments	0.00	0.00	10
Goodwill	141	141	141
Intangible Assets	59	59	59
Other Noncurrent Operating Assets	63	81	101
Total Liabilities & Shareholders' Equity	501	565	823
Total Liabilities	251	278	323
Total Current Liabilities	45	64	112
Short-Term Debt	0.00	0.00	55
Accounts Payable	5.21	4.11	2.86
Accrued Expenses	13	23	15
Current Employee Benefit Liabilities	14	24	26
Other Current Liabilities	13	13	12
Total Noncurrent Liabilities	205	213	212
Capital Lease Obligations	82	91	96
Other Noncurrent Operating Liabilities	123	122	116
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	251	288	499
Total Preferred & Common Equity	251	288	499
Preferred Stock	0.00	0.00	0.00
Total Common Equity	251	288	499
Common Stock	1,855	1,626	1,558
Retained Earnings	-1,605	-1,338	-1,055
Accumulated Other Comprehensive Income / (Loss)	0.01	-0.06	-4.33

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	559	619	681	631	707	747	898
Total Current Assets	210	263	321	280	339	370	500
Cash & Equivalents	127	135	177	168	174	160	163
Restricted Cash	3.83	3.83	3.83	3.83	6.10	6.10	6.10
Short-Term Investments	72	117	134	100	152	189	322
Prepaid Expenses	7.31	7.98	6.35	7.12	6.61	15	8.40
Plant, Property, & Equipment, net	83	86	82	68	63	64	67
Total Noncurrent Assets	266	269	278	284	306	313	331
Long-Term Investments	0.00	0.00	0.00	0.00	0.00	10	30
Goodwill	141	141	141	141	141	141	141
Intangible Assets	59	59	59	59	59	59	59
Other Noncurrent Operating Assets	67	69	79	84	106	103	100
Total Liabilities & Shareholders' Equity	559	619	681	631	707	747	898
Total Liabilities	267	279	306	266	352	319	332
Total Current Liabilities	47	51	53	67	112	103	115
Short-Term Debt	0.00	0.00	0.00	0.00	58	57	59
Accounts Payable	2.99	3.82	6.10	9.93	3.09	2.33	3.99
Accrued Expenses	15	21	20	19	18	13	15
Current Employee Benefit Liabilities	18	16	14	24	20	17	25
Other Current Liabilities	11	10.00	13	13	13	13	12
Total Noncurrent Liabilities	220	228	253	199	240	216	217
Capital Lease Obligations	85	89	93	83	100	102	100
Other Noncurrent Operating Liabilities	134	140	160	116	140	114	117
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	292	340	375	366	355	428	566
Total Preferred & Common Equity	292	340	375	366	355	428	566
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	292	340	375	366	355	428	566
Common Stock	1,848	1,836	1,821	1,616	1,607	1,567	1,547
Retained Earnings	-1,556	-1,496	-1,446	-1,250	-1,251	-1,137	-974
Accumulated Other Comprehensive Income / (Loss)	0.05	-0.02	-0.02	-0.20	-0.87	-2.14	-6.41

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	3.27%	-4.28%	25.45%
EBIT Growth	5.44%	-7.30%	23.38%
NOPAT Growth	6.97%	-7.55%	23.63%
Net Income Growth	5.82%	-5.11%	24.29%
EPS Growth	20.55%	-2.10%	33.18%
Operating Cash Flow Growth	12.00%	12.57%	-15.53%
Free Cash Flow Firm Growth	-20.22%	40.35%	22.71%
Invested Capital Growth	3.81%	-19.50%	67.03%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	10.25%	-0.68%	10.37%
EBIT Q/Q Growth	11.28%	-3.12%	9.58%
NOPAT Q/Q Growth	12.72%	-3.11%	9.76%
Net Income Q/Q Growth	12.77%	-2.78%	10.10%
EPS Q/Q Growth	16.55%	-1.39%	-13.49%
Operating Cash Flow Q/Q Growth	2.10%	8.68%	10.50%
Free Cash Flow Firm Q/Q Growth	9.06%	4.89%	32.41%
Invested Capital Q/Q Growth	0.41%	-4.21%	3.53%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	96.22%	96.61%	98.62%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-99.17%	-72.00%	-43.90%
Cash Return on Invested Capital (CROIC)	-114.34%	-86.46%	-163.64%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-99.17%	-72.00%	-43.90%
Return on Equity Simple (ROE_SIMPLE)	-106.49%	-98.52%	-53.97%
Net Operating Profit after Tax (NOPAT)	-191	-205	-191
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-78.69%	-38.35%	-17.65%
Return On Investment Capital (ROIC_SIMPLE)	-57.47%	-54.23%	-29.33%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-277	-293	-273
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-260	-269	-258
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.45	2.80	1.51
Price to Tangible Book Value (P/TBV)	7.18	9.17	2.52
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.65	4.05	2.21
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.33	0.32	0.30
Long-Term Debt to Equity	0.33	0.32	0.19
Financial Leverage	-0.36	-0.52	-0.73
Leverage Ratio	1.98	1.76	1.59
Compound Leverage Factor	1.91	1.70	1.57
Debt to Total Capital	24.58%	24.02%	23.24%
Short-Term Debt to Total Capital	0.00%	0.00%	8.51%
Long-Term Debt to Total Capital	24.58%	24.02%	14.74%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	75.42%	75.98%	76.76%
Debt to EBITDA	-0.31	-0.34	-0.59
Net Debt to EBITDA	0.29	0.44	1.12
Long-Term Debt to EBITDA	-0.31	-0.34	-0.37
Debt to NOPAT	-0.43	-0.44	-0.79
Net Debt to NOPAT	0.39	0.58	1.51
Long-Term Debt to NOPAT	-0.43	-0.44	-0.50
Altman Z-Score	-5.16	-2.97	-1.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.54	3.31	3.99
Quick Ratio	3.36	3.18	3.80
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-197	-164	-275
Operating Cash Flow to CapEx	-667.52%	-1,265.88%	-1,389.39%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	176	169	210
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	6.46	-41	84
Enterprise Value (EV)	289	686	464
Market Capitalization	364	804	753
Book Value per Share	$1.12	$1.46	$2.62
Tangible Book Value per Share	$0.23	$0.44	$1.57
Total Capital	332	378	651
Total Debt	82	91	151
Total Long-Term Debt	82	91	96
Net Debt	-75	-118	-289
Capital Expenditures (CapEx)	33	20	21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-41	-60	-42
Debt-free Net Working Capital (DFNWC)	115	149	388
Net Working Capital (NWC)	115	149	333
Net Nonoperating Expense (NNE)	76	78	79
Net Nonoperating Obligations (NNO)	-75	-118	-289
Total Depreciation and Amortization (D&A)	17	25	16
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.16)	($1.46)	($1.43)
Adjusted Weighted Average Basic Shares Outstanding	230.89M	194.54M	188.34M
Adjusted Diluted Earnings per Share	($1.16)	($1.46)	($1.43)
Adjusted Weighted Average Diluted Shares Outstanding	230.89M	194.54M	188.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	225.02M	220.45M	191.36M
Normalized Net Operating Profit after Tax (NOPAT)	-191	-205	-191
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	43.25%	-2,329.91%	55.69%	-33.95%	-1.92%	103.19%	-61.50%	-182.92%	27.68%	-2.16%
EBIT Growth	44.02%	-3,228.17%	54.03%	-31.48%	-10.44%	97.82%	-59.19%	-164.42%	26.07%	-3.44%
NOPAT Growth	43.87%	-1,882.24%	57.54%	-31.73%	-10.80%	96.38%	-59.51%	-165.27%	26.50%	-3.30%
Net Income Growth	44.31%	-6,189.84%	55.88%	-30.87%	-9.54%	101.16%	-57.32%	-161.14%	27.35%	-2.23%
EPS Growth	52.27%	0.00%	64.41%	-13.95%	-4.76%	100.00%	-51.28%	-152.94%	-68.00%	2.17%
Operating Cash Flow Growth	9.23%	18.46%	0.44%	17.21%	31.69%	1.92%	17.74%	-2.01%	30.91%	-28.34%
Free Cash Flow Firm Growth	-87.73%	-271.47%	47.50%	95.03%	84.19%	109.46%	83.19%	14.78%	23.06%	-289.05%
Invested Capital Growth	3.81%	-0.96%	-4.92%	-30.84%	-19.50%	-12.99%	-15.22%	132.71%	67.03%	2,634.47%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	22.95%	-17.84%	53.54%	-34.54%	-3,127.66%	102.34%	-40.42%	-2.37%	5.37%	-18.72%
EBIT Q/Q Growth	18.84%	-16.84%	51.59%	-21.95%	-4,725.29%	98.39%	-38.45%	-2.43%	4.91%	-18.04%
NOPAT Q/Q Growth	17.64%	-25.09%	55.41%	-22.19%	-2,808.45%	97.32%	-38.35%	-2.77%	5.10%	-18.22%
Net Income Q/Q Growth	18.11%	-19.15%	53.21%	-21.97%	-9,054.98%	100.86%	-38.81%	-2.09%	5.49%	-17.46%
EPS Q/Q Growth	16.00%	-19.05%	57.14%	-11.36%	0.00%	100.00%	-37.21%	-2.38%	6.67%	-15.38%
Operating Cash Flow Q/Q Growth	8.99%	11.48%	10.80%	-26.32%	18.24%	-8.08%	25.82%	-4.21%	-17.39%	9.35%
Free Cash Flow Firm Q/Q Growth	-1.28%	-62.12%	-178.37%	58.93%	-192.51%	149.64%	73.64%	-30.66%	44.68%	11.74%
Invested Capital Q/Q Growth	0.41%	1.38%	12.79%	-9.58%	-4.21%	-2.67%	-17.96%	5.25%	3.53%	-5.16%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	99.95%	100.00%	100.00%	100.06%	100.00%	100.00%
Interest Burden Percent	96.74%	95.87%	94.01%	97.25%	97.29%	-52.40%	97.96%	97.65%	98.03%	98.64%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-99.17%	-92.90%	-70.51%	-76.82%	-72.00%	-59.15%	-72.73%	-56.67%	-43.90%	-42.94%
Cash Return on Invested Capital (CROIC)	-114.34%	-123.33%	-94.85%	-83.06%	-86.46%	-90.84%	-113.75%	-223.45%	-163.64%	-386.63%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-99.17%	-92.90%	-70.51%	-76.82%	-72.00%	-59.15%	-72.73%	-56.67%	-43.90%	-42.94%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-104.56%	-72.10%	-82.26%	0.00%	-75.33%	-101.87%	-74.76%	0.00%	-52.96%
Net Operating Profit after Tax (NOPAT)	-36	-43	-35	-78	-63	-2.18	-81	-59	-57	-60
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-13.97%	-10.90%	-9.25%	-13.98%	-12.13%	1.15%	-10.89%	-5.73%	-5.20%	-4.18%
Return On Investment Capital (ROIC_SIMPLE)	-10.72%	-	-	-	-16.76%	-	-	-	-8.80%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-51	-63	-53	-111	-91	-1.88	-116	-84	-82	-86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-45	-58	-50	-107	-79	2.62	-112	-80	-78	-82
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.45	3.16	3.56	5.88	2.80	2.08	3.21	1.46	1.51	2.02
Price to Tangible Book Value (P/TBV)	7.18	9.99	8.65	12.57	9.17	4.59	7.35	2.74	2.52	3.12
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.65	4.61	6.04	12.94	4.05	3.24	5.33	1.89	2.21	3.83
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.33	0.29	0.26	0.25	0.32	0.23	0.45	0.37	0.30	0.28
Long-Term Debt to Equity	0.33	0.29	0.26	0.25	0.32	0.23	0.28	0.24	0.19	0.18
Financial Leverage	-0.36	-0.47	-0.49	-0.53	-0.52	-0.59	-0.60	-0.72	-0.73	-0.85
Leverage Ratio	1.98	1.81	1.91	1.78	1.76	1.64	1.69	1.59	1.59	1.53
Compound Leverage Factor	1.92	1.73	1.79	1.73	1.72	-0.86	1.65	1.55	1.56	1.51
Debt to Total Capital	24.58%	22.62%	20.68%	19.85%	24.02%	18.56%	30.89%	27.05%	23.24%	21.96%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	11.37%	9.75%	8.51%	8.19%
Long-Term Debt to Total Capital	24.58%	22.62%	20.68%	19.85%	24.02%	18.56%	19.51%	17.31%	14.74%	13.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	75.42%	77.38%	79.32%	80.15%	75.98%	81.44%	69.11%	72.95%	76.76%	78.04%
Debt to EBITDA	-0.31	-0.30	-0.39	-0.31	-0.34	-0.31	-0.45	-0.51	-0.59	-0.55
Net Debt to EBITDA	0.29	0.41	0.73	0.75	0.44	0.71	0.49	0.67	1.12	1.26
Long-Term Debt to EBITDA	-0.31	-0.30	-0.39	-0.31	-0.34	-0.31	-0.29	-0.33	-0.37	-0.35
Debt to NOPAT	-0.43	-0.39	-0.50	-0.42	-0.44	-0.42	-0.62	-0.70	-0.79	-0.75
Net Debt to NOPAT	0.39	0.54	0.94	0.99	0.58	0.95	0.67	0.91	1.51	1.72
Long-Term Debt to NOPAT	-0.43	-0.39	-0.50	-0.42	-0.44	-0.42	-0.39	-0.45	-0.50	-0.47
Altman Z-Score	-3.67	-1.83	-0.66	1.29	-1.79	-0.65	-0.69	-0.90	-0.24	0.74
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.54	4.47	5.20	6.07	3.31	4.19	3.02	3.60	3.99	4.36
Quick Ratio	3.36	4.23	4.96	5.88	3.18	4.03	2.91	3.40	3.80	4.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-42	-42	-26	-9.20	-22	24	-49	-185	-142	-256
Operating Cash Flow to CapEx	-10,816.74%	-1,266.04%	-448.38%	-414.21%	-369.92%	-2,845.95%	-3,728.66%	-3,643.01%	-1,652.91%	-1,489.56%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	176	175	173	153	169	177	182	221	210	203
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	6.46	-1.70	-8.94	-68	-41	-26	-33	126	84	196
Enterprise Value (EV)	289	808	1,042	1,982	686	573	968	419	464	779
Market Capitalization	364	925	1,209	2,204	804	762	1,141	626	753	1,141
Book Value per Share	$1.12	$1.31	$1.53	$1.70	$1.46	$1.86	$1.85	$2.24	$2.62	$2.98
Tangible Book Value per Share	$0.23	$0.42	$0.63	$0.80	$0.44	$0.84	$0.81	$1.19	$1.57	$1.93
Total Capital	332	378	428	468	378	449	514	587	651	725
Total Debt	82	85	89	93	91	83	159	159	151	159
Total Long-Term Debt	82	85	89	93	91	83	100	102	96	100
Net Debt	-75	-117	-167	-222	-118	-189	-173	-207	-289	-363
Capital Expenditures (CapEx)	0.44	4.09	13	16	14	2.23	1.58	2.18	4.60	4.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-41	-40	-43	-47	-60	-60	-47	-31	-42	-47
Debt-free Net Working Capital (DFNWC)	115	163	213	268	149	213	285	324	388	445
Net Working Capital (NWC)	115	163	213	268	149	213	227	267	333	385
Net Nonoperating Expense (NNE)	13	17	16	30	25	-3.17	33	23	23	25
Net Nonoperating Obligations (NNO)	-75	-117	-167	-222	-118	-189	-173	-207	-289	-363
Total Depreciation and Amortization (D&A)	5.69	4.06	3.90	3.75	11	4.50	4.45	4.35	4.20	4.02
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.21)	($0.25)	($0.21)	($0.49)	($0.44)	$0.00	($0.59)	($0.43)	($0.42)	($0.45)
Adjusted Weighted Average Basic Shares Outstanding	230.89M	235.41M	234.44M	217.29M	194.54M	196.98M	192.54M	191.23M	188.34M	189.30M
Adjusted Diluted Earnings per Share	($0.21)	($0.25)	($0.21)	($0.49)	($0.44)	$0.00	($0.59)	($0.43)	($0.42)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	230.89M	235.41M	234.44M	217.29M	194.54M	200.47M	192.54M	191.23M	188.34M	189.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	225.02M	223.27M	222.47M	221.50M	220.45M	197.13M	196.94M	191.50M	191.36M	190.73M
Normalized Net Operating Profit after Tax (NOPAT)	-36	-43	-35	-78	-63	-1.53	-81	-59	-57	-60
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Sana Biotechnology's Financials

When does Sana Biotechnology's fiscal year end?

According to the most recent income statement we have on file, Sana Biotechnology's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sana Biotechnology's net income changed over the last 2 years?

The last 5 years of Sana Biotechnology's net income performance:

2022: -$269.48 million
2023: -$283.26 million
2024: -$266.76 million

Find out what analysts predict for Sana Biotechnology in the coming months.

What is Sana Biotechnology's operating income?

Sana Biotechnology's total operating income in 2024 was -$272.72 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $272.72 million

How has Sana Biotechnology revenue changed over the last 2 years?

Over the last 2 years, Sana Biotechnology's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Sana Biotechnology have?

Sana Biotechnology's total liabilities were at $250.52 million at the end of 2024, a 9.8% decrease from 2023, and a 22.5% decrease since 2022.

How much cash does Sana Biotechnology have?

In the past 2 years, Sana Biotechnology's cash and equivalents has ranged from $127.57 million in 2024 to $176.77 million in 2022, and is currently $127.57 million as of their latest financial filing in 2024.

How has Sana Biotechnology's book value per share changed over the last 2 years?

Over the last 2 years, Sana Biotechnology's book value per share changed from 2.62 in 2022 to 1.12 in 2024, a change of -57.1%.

Related Companies

This page (NASDAQ:SANA) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Financials

Frequently Asked Questions About Sana Biotechnology's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Financials

Annual Income Statements for Sana Biotechnology

Quarterly Income Statements for Sana Biotechnology

Annual Cash Flow Statements for Sana Biotechnology

Quarterly Cash Flow Statements for Sana Biotechnology

Annual Balance Sheets for Sana Biotechnology

Quarterly Balance Sheets for Sana Biotechnology

Annual Metrics And Ratios for Sana Biotechnology

Quarterly Metrics And Ratios for Sana Biotechnology

Frequently Asked Questions About Sana Biotechnology's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools